1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Parmax Pharma Ltd.

Parmax Pharma Ltd.

BBSE:PARMAX
136.40
INR
-1.35
(-0.98%)
-3.20EPS
292.18MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
31.81
32.11
55.95
70.04
48.78
41.5
29.54
80.81
32.03
49.18
Basic EPS, GAAP
0.11
0.07
-0.01
-0.02
- -
0.21
1.15
2.02
0.38
-0.28
-15.37
-6
-11
-3.2
Free Cash Flow per Basic Share
-0.04
-0.17
-0.01
-1.86
-0.94
-6.65
1.14
1.01
-2.09
-1.62
-4.77
-3.89
-8.61
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.68
11.08
12.2
12.18
12.18
12.39
13.54
15.55
15.93
15.65
0.28
-5.32
-16.43
- -
Tangible Book Value per Share
10.68
11.08
12.2
12.18
12.18
12.39
13.54
15.55
15.93
15.65
0.28
-5.32
-16.43
- -
Basic Weighted Avg Shares
3
3
4
4
4
4
4
4
4
4
4
3
4
4
Sales/Revenue/Turnover
- -
- -
- -
- -
119
120
209
262
183
154
111
282
121
184
Operating Margin (%)
- -
- -
- -
- -
-0.07
0.69
5.89
7.55
5.67
5.21
-42.07
-2.75
-38.37
-20.45
Depreciation Expense
- -
- -
- -
- -
11
10
10
19
19
19
17
10
10
13
Net Income, GAAP
- -
- -
- -
- -
- -
1
4
8
1
-1
-58
-21
-42
-12
Effective Tax Rate (%)
9.25
37.53
133.13
253.84
67.2
19.8
41.33
37.57
53.34
325.63
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
0.66
2.05
2.88
0.78
-0.67
-52.03
-7.42
-34.34
-6.5
Working Capital
15
15
16
16
-10
-8
-14
-9
-8
4
-34
-41
-60
- -
LT Debt
9
8
5
10
20
53
50
54
45
45
59
77
115
- -
Total Equity
40
41
46
46
46
46
51
58
60
59
1
-20
-61
- -
Return on Invested Capital (%)
-0.36
-0.3
0.32
-0.22
-0.05
0.79
4.29
8.36
2.5
-7.89
- -
- -
- -
- -
Return on Capital (%)
0.74
0.46
-0.08
-0.22
0.19
1.09
4.86
8.9
2.69
-8.63
- -
- -
- -
- -
Return on Common Equity (%)
0.91
0.55
-0.09
-0.17
0.01
1.71
8.84
13.86
2.4
-1.76
-192.93
- -
- -
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
5
- -
LT Borrowings
- -
115
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
126
106
292

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
167
- -
Cash, Cash Equivalents & STI
- -
6
- -
Accounts Receivable, Net
- -
32
- -
Inventories
- -
78
- -
Total Current Liabilities
- -
227
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
5
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-185.05%
-375.25%
209.14%
Free Cash Flow
1,449.87%
-3.53%
139.75%
Net Income, GAAP
2,013.2%
1,041.19%
98.62%
Sales/Revenue/Turnover
- -
4.79%
-57.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
78
21
63
48
282
2026
19
25
43
33
121
2027
82
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.03
-1.88
-1.05
-4
-6
2026
-2.04
-5.56
-1.96
-1.56
-11
2027
5.88
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Umang Alkesh Gosalia
Full Time Employees
9
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No. 20, Survey No. 52 Rajkot GU India 360311
IPO Date
Mar 16, 2017
Website
parmaxpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Parmax Pharma Limited Parmax Pharma Limited (PARMAX.BO) manufactures and sells bulk drugs, drug intermediates, and specialty chemicals in India. The company produces active pharmaceutical ingredients including historical products such as Ampicillin, Amoxycillin, Cephalexin, and Nalidixic Acid; it also engages in contract manufacturing operations using Quality by Design techniques, current Good Manufacturing Practices, and flow chemistry for hazardous and cryogenic reactions. Operations leverage in-house production capabilities and strategic sourcing partnerships to serve pharmaceutical customers primarily in the Indian market. Incorporated in 1994 and headquartered in Rajkot, Gujarat, at Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, the company went public via IPO in 1996 before a temporary discontinuation of activities. Parmax Pharma Limited plans to expand into formulations of tablets, capsules, ointments, and injectables; it advances sustainable manufacturing through a modular plant commissioning for intermediate-to-API processes and maintains leadership via new product offerings and cost efficiencies.